BIMI - Earnings announcements

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) --  BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang hospitals, that are held for sale, were accounted for separately. Net loss for the three months ended September 30, 2023 and 2022 was $3,134,072 and $3,099,662, respectively, whi

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022, revenue increased by $3,211,558, due to the inclusion of the revenues of Phenix Bio Inc., which was acquired on March 15, 2023. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang h

NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended March 31, 2023. The Company reported a significant decrease in net losses and notable improvements in working capital, underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the three months ended March 31, 2023 and 2022 were $3,197,637 and $2,714,711, respectively. The revenues for the three months ended March 31, 2023 were primarily attributable to the revenues from sales of healthcare products by Phenix Bio Inc., a newly acquired subsidiary, and  fr

NEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a healthcare products and services provider, today announced its financial results for the six months ended June 30, 2022. Revenues for the six months ended June 30, 2022 and 2021 were $9,947,109 and $11,424,991, respectively. Compared with the same period in 2021, revenue decreased by $1,477,882, mainly due to the decrease in pharmaceutical sales of $3,615,357. Cost of revenues for the six months ended June 30, 2022 and 2021 were $7,263,179 and $8,867,894, respectively. The decrease primarily reflected the decrease in revenues of most of our principal

NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a healthcare products and services provider, today announced its financial results for the quarter ended March 31, 2022. Revenues for the three months ended March 31, 2022 and 2021 were $5,019,748 and $2,168,004, respectively. Compared with the same period in 2021, revenue increased by $2,851,744 in 2022, mainly due to the $2,073,608 increase in sales of medical devices and $880,202 increase in medical services revenues. The increase in medical device sales is mainly due to higher demand during the first quarter of 2022. The 2022 medical services revenues reflect the r

NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a healthcare products and services provider, today announced its financial results for the fiscal year ended December 31, 2021. Revenues for the years ended December 31, 2021 and 2020 were $27,079,795 and $12,844,902, respectively. The increase of $14,234,893 is mainly due to the full year of revenues of the Guanzan Group, which was acquired in March 2020 and acquisitions of the Guoyitang, Qiangsheng, Eurasia and Minkang hospitals in 2021. For the year ended December 31, 2021, the revenues of the retail pharmacies, wholesale medical devices, wholesale pharmaceuticals

NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) --  BOQI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a leading healthcare products and services provider in China, today announced its financial results for the first quarter ended March 31, 2021. First Quarter 2021 Financial Highlights Revenues grew by $1.75 million, or by 423%, to $2.17 million for the first quarter of 2021 from $0.41 million in the same period of 2020. Gross profit increased by $0.51 million, or by 620%, to $0.59 million for the first quarter 2021 from $0.08 million in the same period of 2020. Gross margin increased to 27.32% for the first quarter 2021 from 19.84% in the

NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) announced its financial results for the fiscal year ended December 31, 2020. Fiscal Year 2020 Financial Highlights: Total revenues of $12,844,902 in the year ended December 31, 2020.Gross profit of $2,442,817 in the year ended December 31, 2020.Gross profit margin of 19% in the year ended December 31, 2020. Mr. Tiewei Song, Chief Executive Officer and President of BOQI International Medical Inc., commented, “We are proud to announce that our revenues reached over $12.8 million in 2020 due to the acquisition of Guanzan Group, which generated millions of revenues from the

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”) today announces the signing of a Memorandum of Understanding (MOU) with Chaohu Zhongshan Minimally Invasive Hospital (“Chaohu Hospital”) on November 27, 2020. Pursuant to the MOU, BOQI International Medical Inc. and Chaohu Zhongshan Minimally Invasive Hospital have been reached a preliminary consensus on mergers and acquisitions. Both BIMI and Chaohu Hospital agreed to share their customer resources as well as co-develop franchisees and members locally after signing this MOU. And they agreed to sign a Stock Purchase Agreement(“Agreement”) after completing the relevant as